Participated · Seed · May 2025

Modular DS provides a bilingual (English and Spanish) SaaS platform that centralizes routine WordPress maintenance tasks such as backups, plugin updates, uptime monitoring, and client reporting. The company positions itself as a user-friendly, scalable alternative to larger competitors like ManageWP and MainWP, with a focus on clean UI and responsive support. Modular DS recently launched version 2.0 of its platform and is aiming to expand its team and product capabilities. The firm is targeting growth in English-speaking markets and seeking to capitalise on rising demand for automation, security, and managed services. Market context noted in the coverage highlights that WordPress powers roughly 43% of all websites globally, underlining the addressable market for professional maintenance tools. The company used the recent funding to accelerate international expansion and product development. Modular DS offers a software platform that centralizes and automates website maintenance tasks—updates, monitoring, backups, reports and security/health analysis—for web professionals and agencies. The product targets professionals who need scalable tooling to manage multiple sites and claims a roadmap of additional features to improve daily workflows. The company reports nearly 1,500 users, mainly in Spain and Latin America, and positions itself as the first Spanish-language alternative in its category. Modular DS intends to use new funding to grow awareness among potential users and continue product development. The team was founded by Héctor de Prada and David Gómez in León and built experience previously through their consultancy Uniqoders. After almost two years since first release and operating alongside consulting work, the founders say the round lets them focus full time on scaling the product.

Participated · Equity · Nov 2024

Tebrio is a biotechnology company based in Salamanca that produces and processes the Tenebrio molitor insect into ingredients for animal feed, soil and plant nutrition, and industrial polymers. Using proprietary, patented technology, it aims to industrialize mass breeding of these insects while advancing sustainability, claiming a lower carbon footprint and the use of 90% less water and 80% less arable land than other natural-based solutions. For pet food the company offers :oProtein, :oLipids and :oMeal — :oProtein contains 72% protein with total digestibility over 90%, :oLipids is a high-oleic, low-acidity oil, and :oMeal is dehydrated larvae with high palatability. Tebrio currently operates a 3,500-square-meter plant that produces hundreds of tons of protein, fat, biofertilizer and chitosan annually. It is constructing a new 90,000-square-meter facility planned to produce more than 100,000 tons annually and intends to triple its workforce. The company raised €30 million to expand production capacity and support the new facility.

Participated · Equity · Jan 2014

STinser provides complete management of steel as a raw material for industries ranging from automotive to household electrical appliances. Founded in 2009 and based in Burgos, Spain, the company is led by José Ángel González Arias. It currently employs 23 people and reported roughly €10m in revenue in 2013. The company’s core offering centers on steel supply chain and inventory management for industrial customers. STinser intends to use new funding to expand its facilities in Miranda de Ebro (Burgos) and to initiate the exporting process.

Participated · Equity · Oct 2013

Fast Drinks is a Valladolid, Spain-based manufacturer of self-heating cans and beverages. Founded in 2005, the company developed self-heating containers after three years of R&D and launched products under its 2GO brand. Its 2GO range includes black coffee, cappuccino, chocolate, lemon tea and chicken soup consommé, and the company sells in Spain, France, Great Britain, Scandinavia, the USA and Japan. The company raised €3.5m in funding to support growth. Fast Drinks plans to use the funds to position itself as a leading global manufacturer of self-heating packaging and to target sales of 7 million cans worldwide in 2017. The company is led by Javier Gil, Julián Espegel and Rocío Hervella.

Participated · Equity · Feb 2013

Amadix develops tests for early cancer diagnosis that combine molecular analysis with big data and artificial intelligence. The company received a €2.5M grant from the European Innovation Council (EIC) Accelerator. It has begun procedures to obtain a second, €6M equity tranche under the same program. Sodical is a shareholder in Amadix. The EIC selection was highly competitive — more than 4,000 SMEs applied and only 99 were chosen (2.4% success rate). Amadix was among the selected projects led by women (part of the 19% statistic). The funding is intended to accelerate continued development of its diagnostic tests. Amadix, founded in 2010 and based in Valladolid, develops non-invasive blood tests for early cancer screening and molecular diagnosis. Its lead product, ColoFast, is designed to detect colorectal cancer even before symptoms appear. The company also has two tests in development targeting lung and pancreatic cancer. With the new investment, Amadix will complete the clinical validation of ColoFast in Europe. The company estimates it will bring ColoFast to market during 2021. Amadix positions its technology as a simple, high-compliance screening method able to detect precancerous lesions in asymptomatic individuals. Amadix is a biotech firm focused on diagnostic tools in oncology, with its Colofast test designed to detect colon cancer up to fifteen years before symptoms. The company is also developing Diagnolung (early lung‑cancer detection) and Pancreadix (early pancreatic‑cancer detection), both currently in clinical validation. Amadix plans to commercialize its technology from 2020 and is targeting the US and European markets, with interest in exploring China. The company has received prior funding including €2.8M in 2017 following a Horizon 2020 aid and more than €0.5M later from Alentia, and was named best startup at South Summit 2018. Amadix is based in Valladolid. Amadix merged with Transbiomed and focuses on developing diagnostics for lung, colon and prostate cancers. The company is led by Rocío Arroyo and intends to use new funds to continue developing its pipeline and to acquire new biomarkers. Following the transaction, Amadix’s shareholder base includes CRB Bio II FCR, Inveready Seed Capital SCR, Fondo Tecnológico Seguranza FCR, ADE Capital Sodical SCR and the founders of Transbiomed. The deal comprised a €2m financing package, with €1.5m committed by CRB Bio II and €0.5m by Inveready, alongside various public credit financings. The merger with Transbiomed and the fresh capital are positioned to support continued R&D and biomarker acquisition efforts.